SVB Securities analyst David Risinger maintained a Sell rating on AbbVie (ABBV – Research Report) on January 25 and set a price target of $135.00. The company’s shares closed yesterday at $147.40.
According to TipRanks, Risinger is a 4-star analyst with an average return of 5.3% and a 53.82% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Roivant Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AbbVie with a $161.73 average price target.
See the top stocks recommended by analysts >>
Based on AbbVie’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $14.81 billion and a net profit of $3.95 billion. In comparison, last year the company earned a revenue of $14.34 billion and had a net profit of $3.18 billion
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Read More on ABBV:
- Unusually active option classes on open January 18th
- After Alzheimer’s, AbbVie and BioMed X Team Up for More
- AbbVie and Anima Biotech collaborate for mRNA modulators discovery
- AbbVie, Immunome enter collaboration to discover novel antibody-target pairs
- AbbVie, Immunome announce strategic collaboration